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Abstract: We present the first case report of a complete response of metastatic gastroesophageal 
cancer in a chronic hemodialysis patient with irinotecan-based chemotherapy. An elderly 
dialysis patient presented with diffuse liver metastases by a gastroesophageal adenocarcinoma. 
He received combination chemotherapy with 5 fluorouracil and irinotecan. After six months of 
chemotherapy, liver scans show complete remission. The principles, practice, and experience 
of chemotherapy with irinotecan during dialysis are discussed.
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Introduction and background
Metastatic gastric and gastroesophageal carcinoma are known as chemotherapy-
  sensitive tumor types. Many different chemotherapy regimens were therefore 
  developed.1–3 However, little is known on the feasibility and efficiency of chemotherapy 
for these cancer types in patients with severe renal failure.4–6 Only case reports on 
the pharmacology of irinotecan in patients with colon or rectal cancer are available 
at present.7–11 We present the first case of combination chemotherapy in metastatic 
gastroesophageal cancer in a dialysis patient.
Case report
A 73-year-old patient with a longstanding history of ischemic heart disease had been 
on dialysis for two years for vascular renal insufficiency. In September 2004 he was 
admitted for gastrointestinal blood loss. An upper gastrointestinal (GI) endoscopy 
showed a tumor at the gastroesophageal junction. Biopsy revealed adenocarcinoma. 
The computed tomography (CT) scan of the liver showed important liver metastases. 
CA 19.9 was very high: 24925 U/mL (nL  37 U/mL).
The patient was started on chemotherapy, the regimen consisting of l-leukovorin 
250 mg/m², irinotecan 50 mg/m² followed by 5-fluorouracil (5 FU) 2 g/m²/24 h, six 
weeks out of eight.12–13 There was neither significant nausea nor diarrhea. Dialysis was 
continued three times a week, (the patient was on a Monday – Wednesday – Friday 
schedule of dialysis) and chemotherapy was given on the Monday, just after dialysis. 
Only one dose was omitted owing to neutropenia. After four weeks of chemotherapy 
he also underwent a right carotid endarterectomy for an intercurrent transient ischemic 
attack in the right carotid region.
Six months after starting chemotherapy the CT scan of the liver showed a complete 
response of the numerous metastases. (Figures 1 and 2) Endoscopy showed only 
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minimal tumor remnants. Marker studies showed a remarkable 
drop in CA 19.9. (Table 1) Nine months after initiation of 
treatment, however, the liver metastasis and tumor marker 
were progressive again. Second line chemotherapy with 
paclitaxel was started. Doses of chemotherapy were based on 
a number of case reports on paclitaxel for ovarian cancer in 
dialysis patients.14,15 CT scan after two months showed further 
progressive disease. The patient died in hospice 13 months 
after initial start of chemotherapy.
Discussion
The increase in solid tumors in a patient undergoing dialysis 
poses specific problems,16 especially in the choice and 
pharmacology of anticancer drugs, bearing in mind that all 
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Figure 2 Evolution of CA 19.9 under chemotherapy.
Figure 1 A) Initial situation with massive liver metastases in left, right, and caudate lobe of the liver. B) Complete response of diffuse liver metastases after four months of 
irinotecan-based chemotherapy.
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of these drugs were developed in patients with normal liver 
and kidney function. For gastric cancer, 5FU has always 
been the backbone of treatment.1,2 In chronic hemodialysis, 
there are some data on dose reductions with 5FU weekly.17,18 
For gastric cancer, combination chemotherapy is, however, 
necessary to obtain prolonged disease control and even for 
prolonging overall survival.1,2 Combinations of 5FU + cispla-
tin and either docetaxel or epirubicin have therefore become 
standard chemotherapy regimens in gastric cancer.19,20
Besides the aforementioned regimens, irinotecan-based 
combinations were shown to be active in first21 and second 
line gastric cancer.22 Its equivalence (in combination with 
5FU) in first-line metastatic gastric cancer was recently 
established in two studies, both comparing this regimen with 
a combination chemotherapy with cisplatin and 5FU.23,24
Irinotecan is metabolized in the liver to its active 
metabolite SN-38, followed by biliary excretion.6 There is 
no significant renal elimination. The drug was evaluated in 
patients with serum creatinin between 1.6 and 5 mg/dL and 
no unexpected toxicities were seen.25 There are a number of 
case reports on the use of irinotecan during hemodialysis, all 
of which are on patients with metastatic colon cancer.
A first report mentions the use of irinotecan at a dose 
of 50 mg/m² without significant toxicity.7 In two other 
case reports on dialysis patients, both patients were 
started with irinotecan at 50 mg/m². Both reports mention 
that by increasing the dose, prohibitive diarrhea was the 
consequence.8,11
The worst outcome in higher irinotecan doses (above 
125 mg/m²) was demonstrated in two other dialysis patients, 
where these dosages led to extreme GI toxicities and even 
death.9
It can be concluded that irinotecan in terminal renal 
insufficiency should not be given at a dose above 50 mg/m². 
Korean authors have made pharmacologic evaluations on the 
use of irinotecan in small-cell lung cancer patients during 
dialysis. They increased the dose up to 100 mg/m² without 
diarrhea. They noted however that these doses were only 
feasible in patients of Korean descent.26
There is a very recent case report on the combination 
of irinotecan at a dose of 50 mg/m² weekly combined with 
FU1600 mg/m²/24 h/week, leading to disease stabilization at 
six months in a dialysis patients with diffuse bone, cerebral 
and liver metastases of colon cancer.10
Our case report builds on this knowledge of the use of 
irinotecan in metastatic colorectal cancer during dialysis. 
This case report discusses both the weekly dose of irinotecan 
and the 24-hour administration of 5FU in a gastroesophageal 
cancer patient.
Conclusion
This is the first report on the efficacy of irinotecan- and 
fluorouracil-based chemotherapy in a dialysis patient 
with liver metastases of a gastroesophageal carcinoma. 
  Combination chemotherapy of irinotecan and FU was 
extremely well tolerated, without significant delays in admin-
istration. It produced radiographically complete remission of 
the liver metastases, and a normalization of CA 19-9 tumor 
marker, leading to a remarkable overall survival.
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